Boehringer Ingelheim Vetmedica GmbH

Company Premium

Boehringer Ingelheim Animal Health Business Unit

Boehringer Ingelheim is the second largest animal health business in the world, with net sales of 4 billion euros in 2019 and presence in more than 150 markets.

As the lives of animals and humans are intertwined, across the globe, our 10,000 employees are dedicated to enhancing the well-being of both – through science and innovation, as well as with their commitment and passion.

Respect for animals, people and the environment is at the heart of what we do. We develop medicines, services and innovative digital technologies to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society- threatening diseases.

For more information visit: www.boehringer-ingelheim.com/animal-health/overview

 

Send message
Scheme of activation of the common mucosal immune system by oral vaccine

Activation of the common mucosal immune system by oral vaccine

By exploring the mechanisms of the Common Mucosal Immune System (CMIS), orally administered vaccines are capable of activating coordinated immune responses across different mucosal sites in the body. In this content, we explain how local activation in the GALT triggers protective effects in distant mucosal tissues, such as the respiratory tract, thereby expanding the reach of immune protection.

Contact:

Contact us using the following form.

Boehringer Ingelheim Vetmedica GmbH is present in the following categories